Avalon Pharmaceuticals to Present at BIO CEO & Investor Conference 2007
February 08 2007 - 10:00AM
PR Newswire (US)
GERMANTOWN, Md., Feb. 8 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (Nasdaq and NYSE Arca: AVRX), today announced
that Kenneth C. Carter, Ph.D., President and CEO and Michael
Hamilton, M.D., Chief Medical Officer will be presenting and
participating at the BIO CEO & Investor Conference 2007. The
meeting will be held at the Waldorf-Astoria Hotel in New York City
from February 12-14. Dr. Carter is scheduled to provide an update
on the company on Tuesday, February 13, at 11:15 a.m. EST in the
Morgan Room. A live audio webcast of this presentation can be
accessed on Avalon Pharmaceuticals' website,
http://www.avalonrx.com/ and a replay of the presentation will be
available for 90 days following the conference. Dr. Hamilton is
scheduled to participate in the therapeutics workshop entitled,
"Blood-borne Cancers - The Alphabet Soup of Leukemia" on Monday,
February 12 at 3:30 p.m. EST in the Jade Room. About Avalon
Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical
company using its proprietary technology, AvalonRx(R), to discover
and develop cancer therapeutics. Avalon has a lead product in Phase
I clinical development (AVN944 -IMPDH inhibitor), preclinical
programs to discovery inhibitors for the beta-catenin and aurora
pathways and value generating partnerships with MedImmune, Medarex,
and Novartis. Avalon Pharmaceuticals was established in 1999 and is
headquartered in Germantown, Md. About AvalonRx(R) AvalonRx(R) is a
comprehensive, innovative and proprietary suite of technologies
based upon large-scale gene expression analysis. This platform
facilitates drug discovery by expanding the range of therapeutic
targets for drug intervention, including targets and target
pathways frequently considered intractable using conventional HTS
approaches. It allows more informed decisions about which compounds
to advance towards clinical trials, and facilitates drug
development through identification of biomarkers of efficacy that
can stratify patients or provide early indicators of response.
Contacts: Avalon Pharmaceuticals, Inc. Gary Lessing Executive Vice
President & CFO Tel: (301) 556-9900 Fax: (301) 556-9910 Email:
Noonan Russo Wendy Lau (Media) Tel: (212) 845-4272 The Trout Group
LLC Chad Rubin (Investors) Tel: (212) 477-9007 ext. 47 DATASOURCE:
Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing, Executive Vice
President & CFO, Avalon Pharmaceuticals, Inc., +1-301-556-9900,
Fax: +1-301-556-9910, ; or Media: Wendy Lau, Noonan Russo,
+1-212-845-4272; or Investors: Chad Rubin, The Trout Group LLC,
+1-212-477-9007 ext. 47 Web site: http://www.avalonrx.com/
Copyright